Martina Fabricci, Founder of CBEHx, shared a post on LinkedIn:
“A groundbreaking clinical trial in Japan has demonstrated that injecting neural precursor cells derived from induced pluripotent stem (iPS) cells into individuals with spinal cord injuries can lead to significant functional improvements. In this study, one participant regained the ability to stand independently, while another experienced restored movement in their limbs.
The procedure involved reprogramming adult cells into an embryonic-like state to produce neural precursors, which were then implanted at the injury site. Although two other participants did not exhibit notable progress, the overall findings suggest that this approach is safe and holds promise for spinal cord injury treatment. Researchers emphasize the need for larger trials to confirm these results and further explore the potential of iPS cell-based therapies in neuroregeneration.
Read this amazing article at Nature. (2025). First clinical trial of iPS-cell therapy for spinal-cord injury shows promise.”